NEW YORK (GenomeWeb News) - Clarient has acquired an exclusive license to Health Discovery Corporation’s prostate cancer marker and plans to develop and commercialize a test based on the marker, HDC said today.
 
Under the agreement, HDC will receive a 30 percent royalty payment for all prostate cancer tests Clarient performs for third parties using the technology.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.